GLYC News and Press, GlycoMimetics Inc. From 11/03/23

2023-11-03 07:11:37 ET More on GlycoMimetics GlycoMimetics: Q2 2024 Data Readout Makes This Worth A Look, But Cash Is A Problem GlycoMimetics chief medical officer Rock buys 65.4K shares Seeking Alpha’s Quant Rating on GlycoMimetics Historical earnings...

HST Global Inc (HSTC) is expected to report for quarter end 2023-09-30 Air China Ltd ADR - Level I (AIRYY) is expected to report for Q3 2023 GrafTech International Ltd. (EAF) is expected to report $-0.05 for Q3 2023 Cardinal Health Inc. (CAH) is expected to report $1.4 for Q1 2024 ...

Topline results from pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) on track to be reported by end of Q2 2024 NDA filing for uproleselan anticipated by end of 2024 pending outcome of R/R AML pivotal study Initial results for GMI-1687 Phase 1...

GlycoMimetics Inc. (GLYC) is expected to report $-0.14 for Q3 2023

2023-11-02 11:16:09 ET Major earnings expected before the bell on Friday include: Dominion Energy ( D ) Enbridge ( ENB ) EOG Resources ( EOG ) fuboTV ( FUBO ) W. P. Carey ( WPC ) For further details see: Notable earnings before Friday's open

Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board PR Newswire SAN JOSE, Calif. , Oct. 23, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NA...

GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report third quarter 2023 financial results on Friday, November 3, 2023, at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you will be provided with d...

2023-09-26 11:20:50 ET More on GlycoMimetics Seeking Alpha’s Quant Rating on GlycoMimetics Historical earnings data for GlycoMimetics Financial information for GlycoMimetics GlycoMimetics: Q2 2024 Data Readout Makes This Worth A Look, But Cash Is A Pro...

GMI-1687, a highly potent E-selectin antagonist, is being developed as a potential point-of-care treatment for inflammatory diseases with initial focus on sickle cell disease (SCD) Single ascending dose study is expected to randomize approximately 40 healthy volunteers on GMI-1687 vs placebo ...

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will present at the H.C. Wainwright 25 th Annual Global Investment Conference in New York, NY on Wednesday, September 13, 2023 at 11:30 a.m. ET. A live webcast of the presentation will be av...